Neladenoson bialanate

Drug Profile

Neladenoson bialanate

Alternative Names: BAY 1067197

Latest Information Update: 30 May 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Heart failure therapies
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure

Most Recent Events

  • 10 May 2017 Phase-II clinical trials in Chronic heart failure in Austria (PO) (NCT03098979)
  • 10 May 2017 Bayer initiates a phase II trial in Chronic heart failure in Bulgaria and Germany (EudraCT2016-004062-26)
  • 07 Apr 2017 Bayer plans the PANACHE phase II trial for Chronic heart failure in USA, Austria, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Poland, Portugal and Spain (NCT03098979)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top